Activation of TAK1 by MYD88 L265P drives malignant B-cell growth in non-Hodgkin lymphoma

Blood Cancer Journal

Volumn 4, Issue 2, 2014, Pages

  Ansell, S M ^a   Hodge, L S ^a   Secreto, F J ^a   Manske, M ^a   Braggio, E ^b   Price Troska, T ^a   Ziesmer, S ^a   Li, Y ^a   Johnson, S H ^a   Hart, S N ^a   Kocher, J P A ^a   Vasmatzis, G ^a   Chanan Kahn, A ^c   Gertz, M ^a   Fonseca, R ^b   Dogan, A ^a   Cerhan, J R ^a   Novak, A J ^a  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC   (United States)

^c MAYO CLINIC   (United States)

Author keywords

lymphoma; MYD88; TAK1; Waldenstrom

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE; MYELOID DIFFERENTIATION FACTOR 88; TRANSFORMING GROWTH FACTOR BETA ACTIVATED KINASE 1; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6;

ARTICLE; B LYMPHOCYTE; CANCER GENETICS; CANCER GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME ACTIVATION; HUMAN; HUMAN CELL; LARGE CELL LYMPHOMA; NONHODGKIN LYMPHOMA; OLIGOMERIZATION; SIGNAL TRANSDUCTION; WALDENSTROEM MACROGLOBULINEMIA;

EID: 84895459238     PISSN: None     EISSN: 20445385     Source Type: Journal    
DOI: 10.1038/bcj.2014.4     Document Type: Article

References (32)

1. Lohr JG, Stojanov P, Lawrence MS, Auclair D, Chapuy B, Sougnez C et al. Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc Natl Acad Sci USA 2012; 109: 3879-3884.
2. Morin RD, Johnson NA, Severson TM, Mungall AJ, An J, Goya R et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet 2010; 42: 181-185.
3. Morin RD, Mendez-Lago M, Mungall AJ, Goya R, Mungall KL, Corbett RD et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 2011; 476: 298-303.
4. Pasqualucci L, Dominguez-Sola D, Chiarenza A, Fabbri G, Grunn A, Trifonov V et al. Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature 2011; 471: 189-195.
5. Davis RE, Ngo VN, Lenz G, Tolar P, Young RM, Romesser PB et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 2010; 463: 88-92.
6. Lenz G, Davis RE, Ngo VN, Lam L, George TC, Wright GW et al. Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science 2008; 319: 1676-1679.
7. Mandelbaum J, Bhagat G, Tang H, Mo T, Brahmachary M, Shen Q et al. BLIMP1 is a tumor suppressor gene frequently disrupted in activated B cell-like diffuse large B cell lymphoma. Cancer Cell 2010; 18: 568-579.
8. Puente XS, Pinyol M, Quesada V, Conde L, Ordonez GR, Villamor N et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 2011; 475: 101-105.
9. Treon SP, Xu L, Yang G, Zhou Y, Liu X, Cao Y et al. MYD88 L265P somatic mutation in Waldenstrom's macroglobulinemia. N Engl J Med 2012; 367: 826-833.
10. Ngo VN, Young RM, Schmitz R, Jhavar S, Xiao W, Lim KH et al. Oncogenically active MYD88 mutations in human lymphoma. Nature 2011; 470: 115-119.
11. Montesinos-Rongen M, Godlewska E, Brunn A, Wiestler OD, Siebert R, Deckert M. Activating L265P mutations of the MYD88 gene are common in primary central nervous system lymphoma. Acta Neuropathol 2011; 122: 791-792.
12. Xu L, Hunter ZR, Yang G, Zhou Y, Cao Y, Liu X et al. MYD88 L265P in Waldenstrom macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction. Blood 2013; 121: 2051-2058.
13. Landgren O, Staudt L. MYD88 L265P somatic mutation in IgM MGUS. N Engl J Med 2012; 367: 2255-2256; author reply 2256-2257.
14. Poulain S, Roumier C, Decambron A, Renneville A, Herbaux C, Bertrand E et al. MYD88 L265P mutation in Waldenstrom macroglobulinemia. Blood 2013; 121: 4504-4511.
15. Jimenez C, Sebastian E, Del Carmen Chillon M, Giraldo P, Mariano Hernandez J, Escalante F et al. MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenstrom's macroglobulinemia. Leukemia 2013; 27: 1722-1728.
16. Varettoni M, Arcaini L, Zibellini S, Boveri E, Rattotti S, Riboni R et al. Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstrom's macroglobulinemia and related lymphoid neoplasms. Blood 2013; 121: 2522-2528.
17. Qian Y, Commane M, Ninomiya-Tsuji J, Matsumoto K, Li X. IRAK-mediated translocation of TRAF6 and TAB2 in the interleukin-1-induced activation of NFkappa B. J Biol Chem 2001; 276: 41661-41667.
18. Takaesu G, Kishida S, Hiyama A, Yamaguchi K, Shibuya H, Irie K et al. TAB2, a novel adaptor protein, mediates activation of TAK1 MAPKKK by linking TAK1 to TRAF6 in the IL-1 signal transduction pathway. Mol Cell 2000; 5: 649-658.
19. Hodge LS, Novak AJ, Grote DM, Braggio E, Ketterling RP, Manske MK et al. Establishment and characterization of a novel Waldenstrom macroglobulinemia cell line, MWCL-1. Blood 2011; 117: e190-e197.
20. Feldman AL, Dogan A, Smith DI, Law ME, Ansell SM, Johnson SH et al. Discovery of recurrent t(6;7(p25.3;q32.3) translocations in ALK-negative anaplastic large cell lymphomas by massively parallel genomic sequencing. Blood 2011; 117: 915-919.
21. Vasmatzis G, Johnson SH, Knudson RA, Ketterling RP, Braggio E, Fonseca R et al. Genome-wide analysis reveals recurrent structural abnormalities of TP63 and other p53-related genes in peripheral T-cell lymphomas. Blood 2012; 120: 2280-2289.
22. Braggio E, Keats JJ, Leleu X, Van Wier S, Jimenez-Zepeda VH, Valdez R et al. Identification of copy number abnormalities and inactivating mutations in two negative regulators of nuclear factor-kB signaling pathways in Waldenstrom's macroglobulinemia. Cancer Res 2009; 69: 3579-3588.
23. Schop RF, Van Wier SA, Xu R, Ghobrial I, Ahmann GJ, Greipp PR et al. 6q deletion discriminates Waldenstrom macroglobulinemia from IgM monoclonal gammopathy of undetermined significance. Cancer Genet Cytogenet 2006; 169: 150-153.
24. Schop RFJ, Jalal SM, Van Wier SA, Ahmann GJ, Bailey RJ, Kyle RA et al. Deletions of 17p13.1 and 13q14 are uncommon in Waldenstrom macroglobulinemia clonal cells and mostly seen at the time of disease progression. Cancer Genet Cytogenet 2002; 132: 55-60.
25. Wu J, Powell F, Larsen NA, Lai Z, Byth KF, Read J et al. Mechanism and in vitro pharmacology of TAK1 inhibition by (5Z)-7-Oxozeaenol. ACS Chem Biol 2013; 8: 643-650.
26. Gupta M, Han JJ, Stenson M, Maurer M, Wellik L, Hu G et al. Elevated serum IL-10 levels in diffuse large B-cell lymphoma: a mechanism of aberrant JAK2 activation. Blood 2012; 119: 2844-2853.
27. Elsawa SF, Novak AJ, Ziesmer SC, Almada LL, Hodge LS, Grote DM et al. Comprehensive analysis of tumor microenvironment cytokines in Waldenstrom's macroglobulinemia identifies CCL5 as a novel modulator of IL-6 activity. Blood 2011; 118: 5540-5549.
28. Xu L, Hunter ZR, Yang G, Zhou Y, Cao Y, Liu X et al. MYD88 L265P in Waldenstrom's Macroglobulinemia, IgM monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allelespecific PCR. Blood 2013; 121: 2051-2058.
29. Gachard N, Parrens M, Soubeyran I, Petit B, Marfak A, Rizzo D et al. IGHV gene features and MYD88 L265P mutation separate the three marginal zone lymphoma entities and Waldenstrom macroglobulinemia/lymphoplasmacytic lymphomas. Leukemia 2013; 27: 183-189.
30. Schuman J, Chen Y, Podd A, Yu M, Liu HH, Wen R et al. A critical role of TAK1 in B-cell receptor-mediated nuclear factor kappaB activation. Blood 2009; 113: 4566-4574.
31. Sato S, Sanjo H, Takeda K, Ninomiya-Tsuji J, Yamamoto M, Kawai T et al. Essential function for the kinase TAK1 in innate and adaptive immune responses. Nat Immunol 2005; 6: 1087-1095.
32. Buglio D, Palakurthi S, Byth K, Vega F, Toader D, Saeh J et al. Essential role of TAK1 in regulating mantle cell lymphoma survival. Blood 2012; 120: 347-355.